NEW YORK (TheStreet) - Shares of Gilead Sciences (GILD - Get Report) are up by 0.31% to $102.83 in ahead of schedule evening exchanging on Friday, after the organization's hepatitis C treatment medicine aggregates from the earlier week were distributed today, as indicated by Barron's.
UBS expert Matthew Roden distributed a note demonstrating that scripts for the organization's Harvoni treatment rose 13% over the earlier week.
Aggregate scripts for Harvoni and its accomplice treatment Sovaldi were additionally up 13% week over week to 9,135.
.
Two week's ago, Gilead's prescription numbers showed that Harvoni
scripts declined 2%, while combined prescriptions of Sovaldi and Harvoni
also fell 2% to 9,015.
Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy
with a ratings score of A+. TheStreet Ratings Team has this to say
about their recommendation:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.